[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608715":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":28,"locations":34,"responsibleParty":96,"collaborators":25,"id":98,"slug":99,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":25,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":25,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":25,"overallStatus":51,"whyStopped":25,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Forte Biosciences, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"FB102","ACTIVE_COMPARATOR","Participants will receive FB102.",[13],"Drug: FB102",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Matching placebo",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Route of administration- Intravenous (IV)",[9],null,{"type":22,"name":15,"description":23,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":25,"email":33},"Support Officer","CONTACT","+61 3 7050 1941","recruitment@clinibase.com",[35,49,59,68,78,87],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":25},"St Leonards","NOT_YET_RECRUITING","Saint Leonards","New South Wales (nsw)","2065","Australia","AU",{"type":44,"coordinates":45},"Point",[46,47],144.71803,-38.17051,{"lat":47,"lon":46},{"facility":50,"status":51,"city":50,"state":52,"zip":53,"country":41,"countryCode":42,"cosmosGeoPoint":54,"geoPoint":58,"contacts":25},"Coorparoo","RECRUITING","Queensland","4151",{"type":44,"coordinates":55},[56,57],153.05826,-27.49325,{"lat":57,"lon":56},{"facility":60,"status":37,"city":60,"state":61,"zip":62,"country":41,"countryCode":42,"cosmosGeoPoint":63,"geoPoint":67,"contacts":25},"South Yarra","Victoria","3141",{"type":44,"coordinates":64},[65,66],144.99149,-37.83834,{"lat":66,"lon":65},{"facility":69,"status":37,"city":69,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":77,"contacts":25},"Auckland","0632","New Zealand","NZ",{"type":44,"coordinates":74},[75,76],174.76349,-36.84853,{"lat":76,"lon":75},{"facility":79,"status":37,"city":79,"state":80,"zip":81,"country":71,"countryCode":72,"cosmosGeoPoint":82,"geoPoint":86,"contacts":25},"Christchurch","Canterbury","8013",{"type":44,"coordinates":83},[84,85],172.63333,-43.53333,{"lat":85,"lon":84},{"facility":88,"status":37,"city":88,"state":89,"zip":90,"country":71,"countryCode":72,"cosmosGeoPoint":91,"geoPoint":95,"contacts":25},"Palmerston North","Palmerston North Central","4414",{"type":44,"coordinates":92},[93,94],175.61113,-40.35636,{"lat":94,"lon":93},{"type":97,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100608715","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-fb102-in-patients-with-severe-to-very-severe-alopecia-areata-100608715",false,"NCT07205159","A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.","A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.","Inclusion Criteria:\n\n* Males aged 18-60 years and females aged 18-75 years at Screening.\n* Clinical diagnosis of severe to very severe AA with ≥50% scalp hair loss (including AT or AU) confirmed by SALT score and central photo review; no other cause of hair loss.\n\n  * AT = complete scalp hair loss; AU = complete scalp, facial, and body hair loss. Note: There are additional inclusion criteria. The study center will determine if participant meets all of the criteria\n\nExclusion Criteria:\n\n* Other types of alopecia (e.g., diffuse AA, traction, scarring alopecia, telogen effluvium, trichotillomania, chemotherapy-induced hair loss, androgenetic alopecia).\n* Other scalp diseases impacting AA assessment (e.g., psoriasis, dermatitis, tinea capitis).\n* Active systemic diseases causing hair loss (e.g., lupus, thyroiditis, systemic sclerosis, lichen planus, syphilis).\n\nNote: There are additional exclusion criteria. The study center will determine if participant meets all of the criteria","ALL","18 Years","75 Years",{"count":109,"type":110},32,"ESTIMATED","INTERVENTIONAL",[113],"PHASE1","This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).",[116],"Alopecia Areata","2025-11-17",{"date":119,"type":120},"2025-11-20","ACTUAL",{"date":122,"type":120},"2025-10-23",{"date":124,"type":110},"2027-03-10",{"name":5,"class":6},6]